checkAd
    Startseite > Aktien > Gain Therapeutics > Nachrichten
    Gain Therapeutics
    Aktie
    ISIN: US36269B1052 WKN: A2QQZ4 SYM: GANX Land USA
    Zur Watchlist hinzufügen Zum Portfolio hinzufügen
    1,2400
     
    USD
    -34,39 %
    -0,6500 USD
    Letzter Kurs 15.06.24 Nasdaq
    Geldkurs
    14.06.24
    1,2400
     
    USD
    33.500 STK
    Briefkurs
    14.06.24
    1,2500
     
    USD
    1.000 STK

    Gain Therapeutics Aktie kaufen

    Kauf
    Verkauf

    Neueste Nachrichten

    Gain Therapeutics Announces Pricing of $11.0 Million Public Offering
    14.06.24 · globenewswire · Gain Therapeutics
    Gain Therapeutics Announces Proposed Public Offering
    13.06.24 · globenewswire · Gain Therapeutics
    Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024
    30.05.24 · globenewswire · Gain Therapeutics
    Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update
    14.05.24 · globenewswire · Gain Therapeutics
    Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
    24.04.24 · globenewswire · Gain Therapeutics
    Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer
    08.04.24 · globenewswire · Gain Therapeutics
    Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer
    01.04.24 · globenewswire · Gain Therapeutics
    Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update
    26.03.24 · globenewswire · Gain Therapeutics
    Gain Therapeutics to Present at Public Ventures Discovery Day
    15.03.24 · globenewswire · Gain Therapeutics
    Gain Therapeutics Presents Data at the AD/PD 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease
    05.03.24 · globenewswire · Gain Therapeutics
    Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
    27.02.24 · globenewswire · Gain Therapeutics
    Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight
    14.02.24 · globenewswire · Gain Therapeutics